BertoliR, GirardinF, RussmannS, LauterburgBH: Raynaud's phenomenon induced by drugs acting on neurotransmission: Two cases under reboxetine and one under tegaserod. Eur J Clin Pharmacol, 58:717, 2003.
2.
CookeJP, MarshallJM: Mechanisms of Raynaud's disease. Vasc Med, 10:293–307, 2005.
3.
GokcenC, KutukMO, CoskunS: Dose-dependent Raynaud's phenomenon developing from use of atomoxetine in a girl. J Child Adolesc Psychopharmacol, 23:428–430, 2013.
KratochvilCJ, VaughanBS, HarringtonMJ, BurkeWJ: Atomoxetine: A selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder. Expert Opin Pharmacother, 4:1165–1174, 2003.
6.
NaranjoCA, BustoU, SellersEM, SandorP, RuizI, RobertsEA, JanecekE, DomecqC, GreenblattDJ: A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther, 30:239–245, 1981.
7.
SamaCB: Post-traumatic digital gangrene associated with epinephrine use in primary Raynaud's phenomenon: Lesson for the future. Ethiop J Health Sci, 26:401–404, 2016.
